Curated Papers

Here are curated research papers organized by topic.

Recent high-impact research on “AI Drug Discovery” (IF≥30, last 5 years)

1. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. — Feng Ren, Alex Aliper, Jian Chen et al.. Nature biotechnology (2025-01)
2. Current AI technologies in cancer diagnostics and treatment. — Ashutosh Tiwari, Soumya Mishra, Tsung-Rong Kuo. Molecular cancer (2025-06)
3. Unified modeling of 3D molecular generation via atomic interactions with PocketXMol. — Xingang Peng, Ruihan Guo, Fenglin Guo et al.. Cell (2026-02)

Recent high-impact research on “CAR-T therapy” (IF≥30, last 5 years)

1. CAR-T therapy in solid tumors. — Bing Du, Juliang Qin, Boxu Lin et al.. Cancer cell (2025-04)
2. Disarming myeloid resistance in CAR T therapy. — John M Warrington, Nathan Singh. Cancer cell (2025-08)
3. The journey of CAR-T therapy in hematological malignancies. — Junru Lu, Guan Jiang. Molecular cancer (2022-10)
4. Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases. — Xiaomei Chen, Kaifan Liu, Bowen Liu et al.. Journal of hematology & oncology (2025-11)
5. Chimeric antigen receptor T cell therapies for multiple myeloma. — Chao Wu, Lina Zhang, Qierra R Brockman et al.. Journal of hematology & oncology (2019-11)
6. Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. — Zeguang Wu, Jinhong Shi, Qiezhong Lamao et al.. Cell (2025-10)
7. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. — Yufei Lu, Fu Zhao. Molecular cancer (2025-04)
8. Critical care management of chimeric antigen receptor T-cell therapy recipients. — Alexander Shimabukuro-Vornhagen, Boris Böll, Peter Schellongowski et al.. CA: a cancer journal for clinicians (2022-01)
9. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. — Matthias Totzeck, Lars Michel, Yi Lin et al.. European heart journal (2022-05)
10. Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. — Chuan Qin, Ming-Hao Dong, Luo-Qi Zhou et al.. Cell (2025-11)

In recent years, high-impact research on “CRISPR gene editing” (IF≥30, last 5 years) has emerged.

1. CRISPR gene-editing therapies for hypertrophic cardiomyopathy. — Alanna Strong. Nature medicine (2023-02)
2. CRISPR gene editing of angiopoietin-like 3: toward one-time precision therapy for dyslipidaemia. — Amandeep Mondal, Ashish Misra. Signal transduction and targeted therapy (2026-03)
3. Past, present, and future of CRISPR genome editing technologies. — Martin Pacesa, Oana Pelea, Martin Jinek. Cell (2024-02)

Recent high-impact research on “mRNA vaccines” (IF ≥ 30, last 5 years)

1. mRNA vaccine for cancer immunotherapy. — Lei Miao, Yu Zhang, Leaf Huang. Molecular cancer (2021-02)
2. Nanotechnology-based mRNA vaccines. — Shuying Chen, Xiangang Huang, Yonger Xue et al.. Nature reviews. Methods primers (2023)
3. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. — Namit Chaudhary, Drew Weissman, Kathryn A Whitehead. Nature reviews. Drug discovery (2021-11)
4. Advances in COVID-19 mRNA vaccine development. — Enyue Fang, Xiaohui Liu, Miao Li et al.. Signal transduction and targeted therapy (2022-03)
5. mRNA vaccines in disease prevention and treatment. — Gang Zhang, Tianyu Tang, Yinfeng Chen et al.. Signal transduction and targeted therapy (2023-09)
6. mRNA vaccine: a potential therapeutic strategy. — Yang Wang, Ziqi Zhang, Jingwen Luo et al.. Molecular cancer (2021-02)
7. Myocarditis With COVID-19 mRNA Vaccines. — Biykem Bozkurt, Ishan Kamat, Peter J Hotez. Circulation (2021-08)
8. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. — Tina Schmidt, Verena Klemis, David Schub et al.. Nature medicine (2021-09)
9. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. — Prabhu S Arunachalam, Madeleine K D Scott, Thomas Hagan et al.. Nature (2021-08)
10. The influenza universe in an mRNA vaccine. — Alyson A Kelvin, Darryl Falzarano. Science (New York, N.Y.) (2022-11)

In recent years, high-impact research on “single-cell sequencing” (IF≥30, past 5 years) has emerged.

1. Applications of single-cell sequencing in cancer research: progress and perspectives. — Yalan Lei, Rong Tang, Jin Xu et al.. Journal of hematology & oncology (2021-06)
2. Massively parallel single-cell sequencing of diverse microbial populations. — Freeman Lan, Jason Saba, Tyler D Ross et al.. Nature methods (2024-02)
3. Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies. — Shengkang Huang, Xinyu Wang, Yu Wang et al.. Molecular cancer (2023-05)
4. Single-nucleotide variant calling in single-cell sequencing data with Monopogen. — Jinzhuang Dou, Yukun Tan, Kian Hong Kock et al.. Nature biotechnology (2024-05)
5. Using single-cell sequencing technology to detect circulating tumor cells in solid tumors. — Jiasheng Xu, Kaili Liao, Xi Yang et al.. Molecular cancer (2021-08)
6. Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis. — Yingying Han, Dan Wang, Lushan Peng et al.. Journal of hematology & oncology (2022-05)
7. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. — Ansam Sinjab, Guangchun Han, Warapen Treekitkarnmongkol et al.. Cancer discovery (2021-10)
8. Population genetics meets single-cell sequencing. — Tomokazu S Sumida, David A Hafler. Science (New York, N.Y.) (2022-04)

Recent high-impact research on “liquid biopsy” (IF≥30, last 5 years)

1. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. — Qianwei Ye, Sunbin Ling, Shusen Zheng et al.. Molecular cancer (2019-07)
2. How liquid biopsies can change clinical practice in oncology. — G Siravegna, B Mussolin, T Venesio et al.. Annals of oncology : official journal of the European Society for Medical Oncology (2019-10)
3. Optical nanomaterial-based detection of biomarkers in liquid biopsy. — Young Jun Kim, Won-Yeop Rho, Seung-Min Park et al.. Journal of hematology & oncology (2024-03)
4. Liquid Biopsy: From Discovery to Clinical Application. — Catherine Alix-Panabières, Klaus Pantel. Cancer discovery (2021-04)
5. Liquid biopsy: current technology and clinical applications. — Mina Nikanjam, Shumei Kato, Razelle Kurzrock. Journal of hematology & oncology (2022-09)
6. Liquid biopsies across the cancer care continuum. — Blair V Landon, Akshaya V Annapragada, Noushin Niknafs et al.. Nature medicine (2025-12)
7. The functional and clinical roles of liquid biopsy in patient-derived models. — Ziqing Zhu, Erya Hu, Hong Shen et al.. Journal of hematology & oncology (2023-04)
8. Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance. — Elaine Kilgour, Dominic G Rothwell, Ged Brady et al.. Cancer cell (2020-04)
9. Liquid Biopsy May Guide EGFR Inhibitor Treatment. — Unknown. Cancer discovery (2021-08)

Recent high-impact research on the “tumor microenvironment” (IF ≥ 30, past five years)

1. Monocytes in the Tumor Microenvironment. — Stefano Ugel, Stefania Canè, Francesco De Sanctis et al.. Annual review of pathology (2021-01)
2. Metabolic Codependencies in the Tumor Microenvironment. — Prasenjit Dey, Alec C Kimmelman, Ronald A DePinho. Cancer discovery (2021-05)
3. Posttranslational control of lipogenesis in the tumor microenvironment. — Yahui Zhu, Xingrong Lin, Xiaojun Zhou et al.. Journal of hematology & oncology (2022-08)
4. Immunometabolic Interplay in the Tumor Microenvironment. — Irem Kaymak, Kelsey S Williams, Jason R Cantor et al.. Cancer cell (2021-01)
5. Macrophages and Metabolism in the Tumor Microenvironment. — Ilio Vitale, Gwenola Manic, Lisa M Coussens et al.. Cell metabolism (2019-07)
6. Therapeutic Targeting of the Tumor Microenvironment. — Leire Bejarano, Marta J C Jordāo, Johanna A Joyce. Cancer discovery (2021-04)
7. Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines. — Liudmyla Maksymova, Yannick A Pilger, Lutz Nuhn et al.. Molecular cancer (2025-03)
8. Exosome-orchestrated hypoxic tumor microenvironment. — Wanrong Meng, Yaying Hao, Chuanshi He et al.. Molecular cancer (2019-03)
9. B Cell Function in the Tumor Microenvironment. — Stephanie M Downs-Canner, Jeremy Meier, Benjamin G Vincent et al.. Annual review of immunology (2022-04)
10. Kir2.1 channel: Macrophage plasticity in tumor microenvironment. — Umar Al-Sheikh, Lijun Kang. Cell metabolism (2022-11)

In recent years, high-impact research on “brain-computer interfaces” (IF≥30, last 5 years)

1. Brain-computer interfaces for neuropsychiatric disorders. — Lucine L Oganesian, Maryam M Shanechi. Nature reviews bioengineering (2024-08)
2. Longevity of a Brain-Computer Interface for Amyotrophic Lateral Sclerosis. — Mariska J Vansteensel, Sacha Leinders, Mariana P Branco et al.. The New England journal of medicine (2024-08)
3. A brain-computer interface that evokes tactile sensations improves robotic arm control. — Sharlene N Flesher, John E Downey, Jeffrey M Weiss et al.. Science (New York, N.Y.) (2021-05)
4. Implantable hydrogels as pioneering materials for next-generation brain-computer interfaces. — Wasid Ullah Khan, Zhenzhen Shen, Samuel M Mugo et al.. Chemical Society reviews (2025-03)
5. Plug-and-play control of a brain-computer interface through neural map stabilization. — Daniel B Silversmith, Reza Abiri, Nicholas F Hardy et al.. Nature biotechnology (2021-03)

Recent high-impact research on “Alzheimer’s Disease” (IF≥30, last 5 years)

1. Alzheimer disease. — David S Knopman, Helene Amieva, Ronald C Petersen et al.. Nature reviews. Disease primers (2021-05)
2. Immunotherapies for Alzheimer’s disease. — Todd E Golde, Allan I Levey. Science (New York, N.Y.) (2023-12)
3. Lecanemab in Early Alzheimer’s Disease. — Christopher H van Dyck, Chad J Swanson, Paul Aisen et al.. The New England journal of medicine (2023-01)
4. Donanemab in Early Alzheimer’s Disease. — Mark A Mintun, Albert C Lo, Cynthia Duggan Evans et al.. The New England journal of medicine (2021-05)
5. Is Alzheimer disease a disease? — Amos D Korczyn, Lea T Grinberg. Nature reviews. Neurology (2024-04)
6. Prevalence of Alzheimer’s disease pathology in the community. — Dag Aarsland, Anita Lenora Sunde, Diego A Tovar-Rios et al.. Nature (2026-02)
7. Immune Activation in Alzheimer Disease. — Arnaud Mary, Renzo Mancuso, Michael T Heneka. Annual review of immunology (2024-06)
8. Predicting and preventing Alzheimer’s disease. — Eric Topol. Science (New York, N.Y.) (2025-05)
9. Alzheimer’s disease: From immunotherapy to immunoprevention. — Mathias Jucker, Lary C Walker. Cell (2023-09)
10. Genetic Insights into Alzheimer’s Disease. — Caitlin S Latimer, Katherine L Lucot, C Dirk Keene et al.. Annual review of pathology (2021-01)

High-impact authoritative literature on “AI Drug Discovery”

1. Artificial intelligence in drug discovery and development. — Debleena Paul, Gaurav Sanap, Snehal Shenoy et al.. Drug discovery today (2021-01)
2. Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. — Xin Yang, Yifei Wang, Ryan Byrne et al.. Chemical reviews (2019-09)
3. Artificial intelligence in drug development: present status and future prospects. — Kit-Kay Mak, Mallikarjuna Rao Pichika. Drug discovery today (2019-03)
4. Molecular representations in AI-driven drug discovery: a review and practical guide. — Laurianne David, Amol Thakkar, Rocío Mercado et al.. Journal of cheminformatics (2020-09)
5. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. — Alexandre Blanco-González, Alfonso Cabezón, Alejandro Seco-González et al.. Pharmaceuticals (Basel, Switzerland) (2023-06)
6. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. — Andreas Bender, Isidro Cortés-Ciriano. Drug discovery today (2021-02)
7. Dual Use of Artificial Intelligence-powered Drug Discovery. — Fabio Urbina, Filippa Lentzos, Cédric Invernizzi et al.. Nature machine intelligence (2022-03)
8. Deep learning in drug discovery: an integrative review and future challenges. — Heba Askr, Enas Elgeldawi, Heba Aboul Ella et al.. Artificial intelligence review (2023)
9. De novo molecular design and generative models. — Joshua Meyers, Benedek Fabian, Nathan Brown. Drug discovery today (2021-11)
10. Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. — Anita Ioana Visan, Irina Negut. Life (Basel, Switzerland) (2024-02)

High-impact authoritative literature on “CAR-T therapy”

1. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. — Michael M Boyiadzis, Madhav V Dhodapkar, Renier J Brentjens et al.. Journal for immunotherapy of cancer (2018-12)
2. Chimeric antigen receptor T cell therapy: 25years in the making. — Saar Gill, Marcela V Maus, David L Porter. Blood reviews (2016-05)
3. The journey of CAR-T therapy in hematological malignancies. — Junru Lu, Guan Jiang. Molecular cancer (2022-10)
4. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. — Salyka Sengsayadeth, Bipin N Savani, Olalekan Oluwole et al.. EJHaem (2022-01)
5. Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis. — Bin Hou, Yao Tang, Wenhan Li et al.. Disease markers (2019)
6. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. — Matthias Totzeck, Lars Michel, Yi Lin et al.. European heart journal (2022-05)
7. CAR-T cell therapy and infection: a review. — Olivia Bupha-Intr, Gabrielle Haeusler, Lynette Chee et al.. Expert review of anti-infective therapy (2021-06)
8. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. — Robert C Sterner, Rosalie M Sterner. Frontiers in immunology (2022)
9. Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. — Daniel Sur, Andrei Havasi, Calin Cainap et al.. Journal of clinical medicine (2020-01)
10. Critical care management of chimeric antigen receptor T-cell therapy recipients. — Alexander Shimabukuro-Vornhagen, Boris Böll, Peter Schellongowski et al.. CA: a cancer journal for clinicians (2022-01)

High-impact authoritative literature on “CRISPR gene editing”

1. Engineering the Delivery System for CRISPR-Based Genome Editing. — Zachary Glass, Matthew Lee, Yamin Li et al.. Trends in biotechnology (2018-02)
2. Past, present, and future of CRISPR genome editing technologies. — Martin Pacesa, Oana Pelea, Martin Jinek. Cell (2024-02)
3. Cas9 immunity creates challenges for CRISPR gene editing therapies. — Julie M Crudele, Jeffrey S Chamberlain. Nature communications (2018-08)
4. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9. — Ang Li, Mark R Tanner, Ciaran M Lee et al.. Molecular therapy : the journal of the American Society of Gene Therapy (2020-06)
5. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components. — Pardis Kazemian, Si-Yue Yu, Sarah B Thomson et al.. Molecular pharmaceutics (2022-06)
6. Correction of muscular dystrophies by CRISPR gene editing. — Francesco Chemello, Rhonda Bassel-Duby, Eric N Olson. The Journal of clinical investigation (2020-06)
7. A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. — Wen-Wei Zhang, Subir Karmakar, Sreenivas Gannavaram et al.. Nature communications (2020-07)
8. Resources for the design of CRISPR gene editing experiments. — Daniel B Graham, David E Root. Genome biology (2015-11)
9. Towards personalised allele-specific CRISPR gene editing to treat autosomal dominant disorders. — Kathleen A Christie, David G Courtney, Larry A DeDionisio et al.. Scientific reports (2017-11)

High-Impact Authoritative Literature on “mRNA Vaccines”

1. mRNA vaccines - a new era in vaccinology. — Norbert Pardi, Michael J Hogan, Frederick W Porter et al.. Nature reviews. Drug discovery (2018-04)
2. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. — Namit Chaudhary, Drew Weissman, Kathryn A Whitehead. Nature reviews. Drug discovery (2021-11)
3. mRNA vaccine for cancer immunotherapy. — Lei Miao, Yu Zhang, Leaf Huang. Molecular cancer (2021-02)
4. Advances in mRNA Vaccines for Infectious Diseases. — Cuiling Zhang, Giulietta Maruggi, Hu Shan et al.. Frontiers in immunology (2019)
5. Developing mRNA-vaccine technologies. — Thomas Schlake, Andreas Thess, Mariola Fotin-Mleczek et al.. RNA biology (2012-11)
6. Recent advances in mRNA vaccine technology. — Norbert Pardi, Michael J Hogan, Drew Weissman. Current opinion in immunology (2020-08)
7. Advances in COVID-19 mRNA vaccine development. — Enyue Fang, Xiaohui Liu, Miao Li et al.. Signal transduction and targeted therapy (2022-03)
8. Addressing the Cold Reality of mRNA Vaccine Stability. — Daan J A Crommelin, Thomas J Anchordoquy, David B Volkin et al.. Journal of pharmaceutical sciences (2021-03)
9. Nanomaterial Delivery Systems for mRNA Vaccines. — Michael D Buschmann, Manuel J Carrasco, Suman Alishetty et al.. Vaccines (2021-01)
10. The dawn of mRNA vaccines: The COVID-19 case. — Rein Verbeke, Ine Lentacker, Stefaan C De Smedt et al.. Journal of controlled release : official journal of the Controlled Release Society (2021-05)

High-impact authoritative literature on “single-cell sequencing”

1. Advances and applications of single-cell sequencing technologies. — Yong Wang, Nicholas E Navin. Molecular cell (2015-05)
2. Applications of single-cell sequencing in cancer research: progress and perspectives. — Yalan Lei, Rong Tang, Jin Xu et al.. Journal of hematology & oncology (2021-06)
3. Design and Analysis of Single-Cell Sequencing Experiments. — Dominic Grün, Alexander van Oudenaarden. Cell (2015-11)
4. BayesHammer: Bayesian clustering for error correction in single-cell sequencing. — Sergey I Nikolenko, Anton I Korobeynikov, Max A Alekseyev. BMC genomics (2013)
5. Unravelling biology and shifting paradigms in cancer with single-cell sequencing. — Timour Baslan, James Hicks. Nature reviews. Cancer (2017-08)
6. BASiCS: Bayesian Analysis of Single-Cell Sequencing Data. — Catalina A Vallejos, John C Marioni, Sylvia Richardson. PLoS computational biology (2015-06)
7. The single-cell sequencing: new developments and medical applications. — Xiaoning Tang, Yongmei Huang, Jinli Lei et al.. Cell & bioscience (2019)
8. Single-cell sequencing techniques from individual to multiomics analyses. — Yukie Kashima, Yoshitaka Sakamoto, Keiya Kaneko et al.. Experimental & molecular medicine (2020-09)
9. Single-Cell Sequencing of Brain Cell Transcriptomes and Epigenomes. — Ethan J Armand, Junhao Li, Fangming Xie et al.. Neuron (2021-01)
10. A Single-Cell Sequencing Guide for Immunologists. — Peter See, Josephine Lum, Jinmiao Chen et al.. Frontiers in immunology (2018)

Highly Cited Authoritative Literature on “Liquid Biopsy”

1. Liquid biopsies: genotyping circulating tumor DNA. — Luis A Diaz, Alberto Bardelli. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014-02)
2. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. — Catherine Alix-Panabières, Klaus Pantel. Cancer discovery (2016-05)
3. Circulating tumor DNA as a liquid biopsy for cancer. — Ellen Heitzer, Peter Ulz, Jochen B Geigl. Clinical chemistry (2015-01)
4. Circulating tumor DNA and liquid biopsy in oncology. — David W Cescon, Scott V Bratman, Steven M Chan et al.. Nature cancer (2020-03)
5. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. — Qianwei Ye, Sunbin Ling, Shusen Zheng et al.. Molecular cancer (2019-07)
6. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. — Feifei Cheng, Li Su, Cheng Qian. Oncotarget (2016-07)
7. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. — Maha Elazezy, Simon A Joosse. Computational and structural biotechnology journal (2018)
8. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. — Lena Gorgannezhad, Muhammad Umer, Md Nazmul Islam et al.. Lab on a chip (2018-04)
9. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? — Du-Bois Asante, Leslie Calapre, Melanie Ziman et al.. Cancer letters (2020-01)
10. Liquid biopsies. — Evi Lianidou, Klaus Pantel. Genes, chromosomes & cancer (2019-04)

High-impact authoritative literature on “tumor microenvironment”

1. The tumor microenvironment. — Nicole M Anderson, M Celeste Simon. Current biology : CB (2020-08)
2. Tumor microenvironment and therapeutic response. — Ting Wu, Yun Dai. Cancer letters (2017-02)
3. Tumor microenvironment as a therapeutic target in cancer. — Yi Xiao, Dihua Yu. Pharmacology & therapeutics (2021-05)
4. Tumor Microenvironment. — Borros Arneth. Medicina (Kaunas, Lithuania) (2019-12)
5. Tumor microenvironment: Sanctuary of the devil. — Lanlan Hui, Ye Chen. Cancer letters (2015-11)
6. Neutrophils in the Tumor Microenvironment. — Davalyn R Powell, Anna Huttenlocher. Trends in immunology (2016-01)
7. MRI of the tumor microenvironment. — Robert J Gillies, Natarajan Raghunand, Gregory S Karczmar et al.. Journal of magnetic resonance imaging : JMRI (2002-10)
8. Tumor microenvironment in gastric cancers. — Yukiko Oya, Yoku Hayakawa, Kazuhiko Koike. Cancer science (2020-08)
9. Stromal Cells in the Tumor Microenvironment. — Alice E Denton, Edward W Roberts, Douglas T Fearon. Advances in experimental medicine and biology (2018)
10. Metabolic Codependencies in the Tumor Microenvironment. — Prasenjit Dey, Alec C Kimmelman, Ronald A DePinho. Cancer discovery (2021-05)

High-impact authoritative literature on “brain-machine interfaces”

1. Brain computer interfaces, a review. — Luis Fernando Nicolas-Alonso, Jaime Gomez-Gil. Sensors (Basel, Switzerland) (2012)
2. Brain-computer interfaces in neurological rehabilitation. — Janis J Daly, Jonathan R Wolpaw. The Lancet. Neurology (2008-11)
3. A high-performance brain-computer interface. — Gopal Santhanam, Stephen I Ryu, Byron M Yu et al.. Nature (2006-07)
4. Brain-computer interfaces for communication and rehabilitation. — Ujwal Chaudhary, Niels Birbaumer, Ander Ramos-Murguialday. Nature reviews. Neurology (2016-09)
5. Towards passive brain-computer interfaces: applying brain-computer interface technology to human-machine systems in general. — Thorsten O Zander, Christian Kothe. Journal of neural engineering (2011-04)
6. Brain-computer interfaces in medicine. — Jerry J Shih, Dean J Krusienski, Jonathan R Wolpaw. Mayo Clinic proceedings (2012-03)
7. An auditory brain-computer interface (BCI). — Femke Nijboer, Adrian Furdea, Ingo Gunst et al.. Journal of neuroscience methods (2008-01)
8. An MEG-based brain-computer interface (BCI). — Jürgen Mellinger, Gerwin Schalk, Christoph Braun et al.. NeuroImage (2007-07)
9. Brain-Computer Interface Spellers: A Review. — Aya Rezeika, Mihaly Benda, Piotr Stawicki et al.. Brain sciences (2018-03)
10. Progress in Brain Computer Interface: Challenges and Opportunities. — Simanto Saha, Khondaker A Mamun, Khawza Ahmed et al.. Frontiers in systems neuroscience (2021)

High-impact authoritative literature on “Alzheimer’s Disease”

1. Alzheimer’s disease. — Philip Scheltens, Bart De Strooper, Miia Kivipelto et al.. Lancet (London, England) (2021-04)
2. Alzheimer’s disease. — Philip Scheltens, Kaj Blennow, Monique M B Breteler et al.. Lancet (London, England) (2016-07)
3. Alzheimer’s disease. — Kaj Blennow, Mony J de Leon, Henrik Zetterberg. Lancet (London, England) (2006-07)
4. Alzheimer’s disease. — C A Lane, J Hardy, J M Schott. European journal of neurology (2018-01)
5. Alzheimer’s disease. — Clive Ballard, Serge Gauthier, Anne Corbett et al.. Lancet (London, England) (2011-03)
6. Alzheimer’s disease. — Colin L Masters, Randall Bateman, Kaj Blennow et al.. Nature reviews. Disease primers (2015-10)
7. Alzheimer’s disease. — Jose A Soria Lopez, Hector M González, Gabriel C Léger. Handbook of clinical neurology (2019)
8. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. — Randall J Bateman, Paul S Aisen, Bart De Strooper et al.. Alzheimer’s research & therapy (2011-01)
9. Alzheimer’s disease. — Dennis J Selkoe. Cold Spring Harbor perspectives in biology (2011-07)
10. Mitochondrial alterations in Alzheimer’s disease. — Stavros J Baloyannis. Journal of Alzheimer’s disease : JAD (2006-07)

© 2025 MaltSci